https://www.aigom.it/wp-content/uploads/2024/11/LOC-19.11.png1227960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-18 17:42:362024-11-18 17:42:36UGT1A1*28 POLYMORPHISM AND THE RISK OF TOXICITY AND DISEASE PROGRESSION IN PATIENTS WITH BREAST CANCER RECEIVING SACITUZUMAB GOVITECAN.
https://www.aigom.it/wp-content/uploads/2024/11/LOC.12.11.png1134960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-10 14:16:252024-11-10 14:16:25CHARACTERISTICS AND CLINICAL OUTCOMES OF BREAST CANCER IN YOUNG BRCA CARRIERS ACCORDING TO TUMOR HISTOLOGY
https://www.aigom.it/wp-content/uploads/2024/11/loc.15gennaio.png805567Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-09 09:30:282024-11-09 09:30:2815 GENNAIO 2024, VERONA AIGOM-GIST AVANZATI: IL VALORE DELLA GESTIONE MULTIDISCIPLINARE DEL PAZIENTE
https://www.aigom.it/wp-content/uploads/2024/11/ART.5-11.png1238950Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-11-05 04:31:132024-11-05 04:31:13NEOADJUVANT CHEMOTHERAPY WITH OXALIPLATIN AND FLUOROPYRIMIDINE VERSUS UPFRONT SURGERY FOR LOCALLY ADVANCED COLON CANCER: THE RANDOMIZED, PHASE III OPTICAL TRIAL.
https://www.aigom.it/wp-content/uploads/2024/10/ART.29.10.png1181960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-10-28 08:53:462024-10-28 08:53:46NEOADJUVANT DOCETAXEL, OXALIPLATIN, AND S-1 PLUS SURGERY AND ADJUVANT S-1 FOR RESECTABLE ADVANCED GASTRIC CANCER: UPDATED OVERALL SURVIVAL OUTCOMES FROM PHASE III PRODIGY.
https://www.aigom.it/wp-content/uploads/2024/10/ART22.10.png1080960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-10-21 09:26:222024-10-21 09:26:22ELACESTRANT (ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER) VERSUS STANDARD ENDOCRINE THERAPY FOR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER: RESULTS FROM THE RANDOMIZED PHASE III EMERALD TRIAL.
https://www.aigom.it/wp-content/uploads/2024/10/ART.15.10.png1277960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-10-14 07:39:232024-10-14 07:39:23TRASTUZUMAB DERUXTECAN AFTER ENDOCRINE THERAPY IN METASTATIC BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2024/10/aicro8.11.png509750Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-10-10 07:53:212024-10-10 07:53:21AICRO-MENTI A CONTATTO 8 NOVEMBRE 2024 ROMA-MILANO
https://www.aigom.it/wp-content/uploads/2024/10/art.8.10.png1232960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-10-07 07:49:582024-10-07 07:49:58NEOADJUVANT NIVOLUMAB AND IPILIMUMAB IN RESECTABLE STAGE III MELANOMA.
https://www.aigom.it/wp-content/uploads/2024/10/ART.1.10.png1284960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-10-01 07:39:072024-10-01 07:39:07OVERALL SURVIVAL WITH PEMBROLIZUMAB IN EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER.
